JP2015180198A5 - - Google Patents

Download PDF

Info

Publication number
JP2015180198A5
JP2015180198A5 JP2015044097A JP2015044097A JP2015180198A5 JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5 JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5
Authority
JP
Japan
Prior art keywords
serine
serine racemase
barrier function
expression level
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015044097A
Other languages
English (en)
Japanese (ja)
Other versions
JP6854073B2 (ja
JP2015180198A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2015044097A priority Critical patent/JP6854073B2/ja
Priority claimed from JP2015044097A external-priority patent/JP6854073B2/ja
Publication of JP2015180198A publication Critical patent/JP2015180198A/ja
Publication of JP2015180198A5 publication Critical patent/JP2015180198A5/ja
Priority to JP2019186327A priority patent/JP6934925B2/ja
Application granted granted Critical
Publication of JP6854073B2 publication Critical patent/JP6854073B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015044097A 2014-03-05 2015-03-05 表皮セリンラセマーゼ及び/又はd−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 Active JP6854073B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2015044097A JP6854073B2 (ja) 2014-03-05 2015-03-05 表皮セリンラセマーゼ及び/又はd−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法
JP2019186327A JP6934925B2 (ja) 2014-03-05 2019-10-09 セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014043073 2014-03-05
JP2014043073 2014-03-05
JP2015044097A JP6854073B2 (ja) 2014-03-05 2015-03-05 表皮セリンラセマーゼ及び/又はd−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019186327A Division JP6934925B2 (ja) 2014-03-05 2019-10-09 セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤

Publications (3)

Publication Number Publication Date
JP2015180198A JP2015180198A (ja) 2015-10-15
JP2015180198A5 true JP2015180198A5 (de) 2016-04-28
JP6854073B2 JP6854073B2 (ja) 2021-04-07

Family

ID=54328827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015044097A Active JP6854073B2 (ja) 2014-03-05 2015-03-05 表皮セリンラセマーゼ及び/又はd−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法
JP2019186327A Active JP6934925B2 (ja) 2014-03-05 2019-10-09 セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019186327A Active JP6934925B2 (ja) 2014-03-05 2019-10-09 セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤

Country Status (1)

Country Link
JP (2) JP6854073B2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018174286A1 (ja) * 2017-03-24 2018-09-27 味の素株式会社 角層機能改善剤
JP7366428B2 (ja) * 2018-08-27 2023-10-23 Kagami株式会社 乾癬を判定するための皮膚試料の分析方法及びシステム
JP7237689B2 (ja) * 2019-03-28 2023-03-13 株式会社ナリス化粧品 ストレスに起因する皮膚バリア機能改善剤のスクリーニング方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012008146A2 (pt) * 2009-09-14 2019-09-24 Shiseido Co Ltd composição para alívio dos danos causados por meio da irradiação ultravioleta

Similar Documents

Publication Publication Date Title
Khan et al. Molecular and physiological manifestations and measurement of aging in humans
EA201991105A1 (ru) Методы оценки риска с использованием общей и специфической неклеточной днк
BR112014000965B8 (pt) Método, aparelho e meio de armazenamento não transitório
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
JP2018507690A5 (de)
WO2016046640A3 (en) Methods for predicting drug responsiveness
BR112017010190A2 (pt) sistema para medição de características, método de medição
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
MX366369B (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
JP2015180198A5 (de)
JP2015511721A5 (de)
RU2017122187A (ru) Клеточный способ определения эффективности дефибротида
JP2004527244A5 (de)
AU2018275891A1 (en) Articles of manufacture and methods related to toxicity associated with cell therapy
MY196578A (en) Method for Determining Stage of Periodontal Disease
DE602005008710D1 (de) Verfahren zur untersuchung der aktivität von ionenkanälen
MX2020012222A (es) Evaluar la eficacia de composiciones cosmeticas que no se deben enjuagar para proteccion contra contaminantes.
RU2012153849A (ru) Способ оценки токсичности продукции из полимерных и текстильных материалов
Ilić et al. Syphacia obvelata modifies mitogen-activated protein kinases and nitric oxide synthases expression in murine bone marrow cells
WO2012109258A3 (en) Compositions adn methods for monitoring oxalate
Thomaz et al. Redox Behavior and Radical Scavenging Capacity of Hepatoprotective Nutraceutical Preparations
JP2014208601A5 (de)
PL410454A1 (pl) Sposób identyfikowania odpowiedzi chorego na łuszczycę na leczenie genisteiną molekularny test oraz zastosowanie ekspresji genów do wykrywania in vitro łuszczycy
RU2017139718A (ru) Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток
JP2014028787A5 (de)